Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.48 |
| ▸ | TBK1 | Q9UHD2 | 7/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218701 | 0.95 | ACHE (0.45) | ACHETBK1CHEK2IKBKELTA4H | |
| SCHEMBL4834847 | 0.94 | LTA4H (0.47) | ACHETBK1CHEK2IKBKELTA4H | |
| Trifluoroacetic Acid SCHEMBL4846269 | 0.92 | CHEK2 (0.44) | ACHETBK1CHEK2IKBKE | |
| SCHEMBL4838294 | 0.90 | TBK1 (0.48) | ACHETBK1CHEK2IKBKELTA4H | |
| SCHEMBL6218704 | 0.89 | ACHE (0.40) | ACHETBK1CHEK2IKBKELTA4H | |
| SCHEMBL4844406 | 0.89 | ACHE (0.61) | ACHETBK1CHEK2IKBKELTA4H | |
| SCHEMBL4845601 | 0.89 | ACHE (0.48) | ACHETBK1CHEK2IKBKEHRH2 | |
| SCHEMBL4843624 | 0.88 | ACHE (0.50) | ACHETBK1CHEK2IKBKE | |
| SCHEMBL4838273 | 0.88 | CHEK2 (0.51) | ACHETBK1CHEK2IKBKELTA4H | |
| SCHEMBL4844287 | 0.88 | ACHE (0.62) | ACHETBK1CHEK2IKBKEHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | claimed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | claimed |
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | ACHE 1390/4885TBK1 1029/4885CHEK2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.